Villejuif, le 28 janvier 2019

L'étude PREMIS

En oncologie, les médicaments immunostimulants notamment les inhibiteurs de checkpoint immunitaires ciblant PD-1/PD-L1 et CTLA4, révolutionnent le traitement de nombreux cancers. Le nombre de patients traités avec ces molécules s’accroît de manière remarquable avec l’obtention de nombreuses autorisations de mise sur le marché, et la mise en place de nombreux essais cliniques, notamment avec des combinaisons, dans de nombreuses indications.

2019 press releases

• Professor Jean-Charles Soria appointed General Director of Gustave Roussy
  Press release - 16 december 2019
• Pediatric Cancers: Why Some Forms of Leukemia Only Affect Children
  Press release - 29 october 2019

9 janvier 2019

Breast surgery

Fully integrated plastic surgery of the breast

At Gustave Roussy, surgery for breast cancer is no longer synonymous with mutilation.
Cosmetic mammary reconstruction is fully incorporated within the management of this condition at every stage. More than 2,000 patients have surgery each year for breast cancer and more than 500 reconstructive procedures are carried out, making the Institute the leading breast reconstruction centre in France.

Gynaecological surgery

At Gustave Roussy, more than 90% of patients undergoing surgery for uterine cancer (cervical cancer or cancer of the endometrium) have minimally invasive (laparoscopic) surgery. This applies both for surgery involving the uterus itself (simple or extended hysterectomy) and for removal of lymph nodes (node clearance). This surgical technique results in less pain than that experienced following laparotomy (opening of the abdomen), recovery is quicker and normal activities can be resumed earlier.